ABO1009-DP
/ Suzhou Abogen Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
September 21, 2022
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
(clinicaltrials.gov)
- P1/2 | N=48 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 31, 2022
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
(clinicaltrials.gov)
- P1/2 | N=48 | Recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 23, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 23, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 17, 2022
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd. | Trial primary completion date: Aug 2022 ➔ Dec 2022
Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 28, 2022
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 27, 2022
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Suzhou Abogen Biosciences Co., Ltd.
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 7
Of
7
Go to page
1